| KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma G Gao, W Liao, Q Ma, B Zhang, Y Chen, Y Wang Lung Cancer 149, 41-45, 2020 | 57 | 2020 |
| Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: a cost … F Wen, H Zheng, P Zhang, W Liao, K Zhou, Q Li Liver International 41 (5), 1097-1104, 2021 | 51 | 2021 |
| Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China W Liao, J Huang, D Hutton, Q Li Journal of medical economics 22 (4), 344-349, 2019 | 44 | 2019 |
| Comprehensive analysis of EMT-related genes and lncRNAs in the prognosis, immunity, and drug treatment of colorectal cancer Y Yang, M Feng, LL Bai, W Liao, K Zhou, M Zhang, Q Wu, F Wen, W Lei, ... Journal of translational medicine 19, 1-21, 2021 | 41 | 2021 |
| Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma W Liao, J Huang, D Hutton, G Zhu, Q Wu, F Wen, L Bai, Q Li Liver International 39 (12), 2408-2416, 2019 | 39 | 2019 |
| Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: a study based on large-scale sequencing data GQ Zhu, YJ Zhou, LX Qiu, B Wang, Y Yang, WT Liao, YH Luo, YH Shi, ... Carcinogenesis 40 (9), 1077-1085, 2019 | 34 | 2019 |
| Cost-effectiveness of tucatinib in human epidermal growth factor receptor 2–positive metastatic breast cancer from the US and Chinese perspectives Q Wu, W Liao, M Zhang, J Huang, P Zhang, Q Li Frontiers in oncology 10, 1336, 2020 | 26 | 2020 |
| Chronological in vivo imaging reveals endothelial inflammation prior to neutrophils accumulation and lipid deposition in HCD-fed zebrafish H Luo, Q Li, N Wu, Y Shen, W Liao, Y Yang, E Dong, G Zhang, B Liu, ... Atherosclerosis 290, 125-135, 2019 | 21 | 2019 |
| Comparative efficacy and safety between ablative therapies or surgery for small hepatocellular carcinoma: a network meta-analysis GQ Zhu, M Sun, WT Liao, WH Yu, SL Zhou, ZJ Zhou, YH Shi, J Fan, ... Expert Review of Gastroenterology & Hepatology 12 (9), 935-945, 2018 | 17 | 2018 |
| A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis Q Ma, X He, B Zhang, F Guo, X Ou, Q Yang, P Shu, Y Chen, K Li, G Gao, ... Signal Transduction and Targeted Therapy 7 (1), 380, 2022 | 16 | 2022 |
| Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal … Q Wu, W Liao, J Huang, P Zhang, N Zhang, Q Li Oral Oncology 103, 104588, 2020 | 16 | 2020 |
| The role of non-apoptotic cell death in the treatment and drug-resistance of digestive tumors Y Yang, LL Bai, W Liao, M Feng, M Zhang, Q Wu, K Zhou, F Wen, W Lei, ... Experimental Cell Research 405 (2), 112678, 2021 | 14 | 2021 |
| Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese … PF Zhang, F Wen, J Zhou, JX Huang, KX Zhou, QJ Wu, XY Wang, ... Clinical and Translational Oncology 22, 103-110, 2020 | 11 | 2020 |
| Cost-Effectiveness analysis of first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with Ras wild-type metastatic … L Bai, P Zhang, K Zhou, W Liao, Q Li Cancer Management and Research, 10419-10426, 2019 | 9 | 2019 |
| Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective K Zhou, Y Li, W Liao, M Zhang, L Bai, Q Li Oral Oncology 107, 104754, 2020 | 8 | 2020 |
| Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis W Liao, J Huang, Q Wu, G Zhu, X Wang, F Wen, P Zhang, N Zhang, Q Li Oral Oncology 93, 15-20, 2019 | 8 | 2019 |
| Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial J Huang, W Liao, J Zhou, P Zhang, F Wen, X Wang, M Zhang, K Zhou, ... Cancer Management and Research, 4065-4072, 2018 | 8 | 2018 |
| Cost-effectiveness of capecitabine+ irinotecan versus leucovorin+ Fluorouracil+ irinotecan in the second-line treatment of metastatic colorectal cancer in China Q Wu, P Zhang, X Wang, M Zhang, W Liao, Q Li Clinical Therapeutics 42 (11), 2148-2158. e2, 2020 | 7 | 2020 |
| Cost-effectiveness analysis of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine for HER2-negative locally recurrent or metastatic breast cancer Q Wu, X Wang, M Zhang, W Liao, F Wang, Q Li Oncology Research and Treatment 43 (4), 153-159, 2020 | 7 | 2020 |
| Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma Q Wu, Y Qin, W Liao, M Zhang, Y Yang, P Zhang, Q Li Therapeutic Advances in Medical Oncology 14, 17588359211068733, 2022 | 6 | 2022 |
